Risk Profiles for Sensorineural Hearing Loss in Patients with Head and Neck Cancer Receiving Cisplatin-based Chemoradiation.
Sensorineural hearing loss (SNHL) is a significant toxicity experienced by some patients undergoing cisplatin-based chemoradiation therapy for head and neck cancer. Therefore, SNHL risk profiles were created based on demographics, hearing thresholds, and treatment parameters. Thirty-eight patients with squamous cell carcinoma of the head and neck, treated with postoperative or definitive cisplatin-based chemoradiation at the Princess Alexandra Hospital between 2010 and 2013, were retrospectively reviewed. Patients with pretreatment otologic problems were excluded. Regression models analysed the contributions of collected variables. All patients (100%) received multiple audiological assessments, with 21 (55.3%) receiving baseline assessment. The mean hearing deterioration at pure-tone average 1-2-4 kHz was mild (range 22.4-27.6 dB). However, clinically significant SNHL was evident in 37 (97.3%), 24 (63.2%), and 14 (36.8%) patients at 8 kHz and pure-tone averages 0.5-1-2 kHz and 1-2-4 kHz, respectively. Principal component analysis indicated two profiles: (1) low or medium frequency SNHL and (2) high-frequency SNHL. Multivariate analysis demonstrated tobacco consumption (ρ < 0.006) and alcohol intake (ρ < 0.08) predicted high-frequency SNHL (F(3,33) = 3.59, ρ < 0.02, R2 = 0.177), with cumulative cisplatin dose (ρ < 0.006) predicting low and medium frequency SNHL (F(3,34) = 14.81, ρ < 0.001, R2 = 0.528). Although hearing loss rates may be under reported without routine audiological assessment, the incidence of cisplatin-based chemoradiation-induced SNHL, in this study, is high. The proposed predictive model can be used as a prognostic tool and potentially mitigate adverse outcomes.